Surface Oncology
50 Hampshire Street, 8th Floor
Cambridge
Massachusetts
02139
United States
Tel: 617-655-5030
Website: https://www.surfaceoncology.com/
About Surface Oncology
We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families.
Stock Symbol: SURF
87 articles with Surface Oncology
-
Surface Oncology to Participate in Upcoming Investor Conferences - May 17, 2022
5/17/2022
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences.
-
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022
5/9/2022
Surface Oncology reported financial results and corporate highlights for the first quarter of 2022 as well as upcoming anticipated corporate milestones.
-
Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 06, 2022
5/6/2022
Surface Oncology, Inc. announced that the company granted non-qualified stock options to five new employees to purchase an aggregate of 50,000 shares of the company’s common stock with a per share exercise price of $2.33, the closing price of Surface’s common stock as reported by Nasdaq on May 2, 2022.
-
Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting
4/27/2022
Surface Oncology announced that it will share a clinical update on SRF388 in an oral presentation at the American Society of Clinical Oncology 2022 Annual Meeting, to be held June 3-7, 2022 in Chicago, Il.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer
4/14/2022
Surface Oncology today announced the initiation of two Phase 2 clinical studies evaluating SRF388, a potential first-in-class antibody against IL-27.
-
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.
-
Surface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022
4/8/2022
Surface Oncology announced the presentation of new preclinical and translational data for SRF388, a first-in-class antibody targeting IL-27, at the American Association for Cancer Research Annual Meeting 2022, being held in New Orleans, April 8-13, 2022.
-
Surface Oncology Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2022
4/1/2022
Surface Oncology, Inc. announced that Surface’s board of directors granted Theresa Boni, J.D., general counsel and senior vice president, legal, non-qualified stock options to purchase 120,000 shares of the company’s common stock with a per share exercise price of $2.87, the closing price of Surface’s common stock as reported by Nasdaq on April 1, 2022.
-
Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study
3/31/2022
Surface Oncology today announced the first patient has been dosed by GlaxoSmithKline (GSK) in the Phase 1 study of GSK4381562 in patients with solid tumors.
-
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
-
Surface Oncology Appoints Theresa Boni as General Counsel
3/15/2022
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced the appointment of Theresa Boni, J.D., as general counsel and senior vice president, legal.
-
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021
3/2/2022
Surface Oncology today reported financial results and corporate highlights for the fourth quarter and full year 2021, as well as anticipated 2022 corporate milestones.
-
Surface Oncology to Participate in Novel Immuno-Oncology Panel at Cowen’s 42nd Annual Health Care Conference
2/28/2022
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in the “Novel Immuno-Oncology” panel discussion at Cowen’s 42nd Annual Health Care Conference.
-
Surface Oncology to Participate in Citi's 2022 Virtual Immuno-Oncology Summit
2/10/2022
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that company management will participate in a fireside chat during Citi's 2022 Virtual Immuno-Oncology Summit.
-
BioSpace Movers & Shakers, Dec. 17
12/17/2021
As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers. -
Surface Oncology Appoints Denice Torres as Chair of the Board of Directors
12/15/2021
Surface Oncology today announced the appointments of Denice Torres to chair of the board of directors and Ben Hickey to board director.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO)
12/6/2021
Surface Oncology today announced that new data from the ongoing Phase 1 study of SRF617, an antibody targeting CD39, will be presented in a scientific poster at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO), to be held virtually from December 8-11, 2021.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.